Man Group
MRTX

Man Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Man Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-109,491
Closed -$3.91M – 1533
2023
Q2 		$3.96M Buy
+109,491
New +$4.51M 0.01% 970
2023
Q1 		– Sell
-25,000
Closed -$1.12M – 1431
2022
Q4 		$1.13M Sell
25,000
-5,895
-19% -$381K ﹤0.01% 1284
2022
Q3 		$2.16M Buy
+30,895
New +$2.29M 0.01% 1041
2022
Q2 		– Hold
0
– – – 643
2021
Q1 		– Sell
-21,831
Closed -$4.8M – 2035
2020
Q4 		$4.8M Sell
21,831
-2,813
-11% -$608K 0.02% 836
2020
Q3 		$4.09M Sell
24,644
-54,660
-69% -$7.48M 0.02% 916
2020
Q2 		$9.05M Buy
79,304
+71,444
+909% +$6.93M 0.05% 392
2020
Q1 		$604K Buy
+7,860
New +$705K ﹤0.01% 1239
2019
Q4 		– Sell
-58,395
Closed -$4.55M – 1938
2019
Q3 		$4.55M Buy
+58,395
New +$5.48M 0.02% 922
2019
Q2 		– Sell
-14,539
Closed -$1.06M – 2037
2019
Q1 		$1.06M Sell
14,539
-3,661
-20% -$249K ﹤0.01% 1564
2018
Q4 		$772K Buy
18,200
+991
+6% +$39.5K ﹤0.01% 1530
2018
Q3 		$811K Buy
+17,209
New +$958K ﹤0.01% 1733

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Man Group's MRTX Position: Q3 2023 in Review

Man Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 109,491 shares — an estimated $3.91M sold.

Man Group first reported a position in MRTX in Q3 2018 and held it in 11 quarters. The position peaked at $9.05M in Q2 2020. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Man Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Man Group sold 109,491 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.91M.
  • Man Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 11 quarters.
  • Man Group's Mirati Therapeutics, Inc. Common Stock position peaked at $9.05M in Q2 2020.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.